Sign In
Buy HROW
$33.32
+0.460 (+1.40%)
At Close: Jun 03, 2026
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
04:57pm, Tuesday, 24'th Mar 2026
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private o
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
09:18am, Tuesday, 24'th Mar 2026
Opaleye Management Inc. disposed of 198,572 shares indirectly across two days, with a transaction value of roughly $7.8 million based on weighted average prices of $39.15 on March 3 and $39.67 on Marc
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
08:15am, Tuesday, 24'th Mar 2026
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer,
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
07:00am, Wednesday, 18'th Mar 2026
NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstra
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market
02:00pm, Tuesday, 17'th Mar 2026
Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and strong operating leverage. HROW's recent 35% stock pullback post-Q4 2025 is
What Moved Markets This Week
06:43am, Saturday, 07'th Mar 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
09:07am, Wednesday, 04'th Mar 2026
Harrow Inc. (NASDAQ: HROW) posted mixed results for the fourth quarter on Tuesday.
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference
07:00am, Wednesday, 04'th Mar 2026
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade)
06:46am, Wednesday, 04'th Mar 2026
Harrow (HROW) is downgraded to 'Sell' as recent earnings reveal persistent low margins and overvaluation despite a 25% share price drop. FY25 revenue grew 36% YoY to $272.3M, but missed ambitious guid
Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript
05:02pm, Tuesday, 03'rd Mar 2026
Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript
Harrow Shares Collapse, Another Opportunity?
02:24pm, Tuesday, 03'rd Mar 2026
Harrow, Inc. remains a compelling long-term and trading opportunity, especially attractive in the mid-$30s and lower $40s after recent pullbacks. HROW delivered strong Q4 2025 revenue growth of 33% Yo
Why Is Eye-Disease-Focused Harrow Stock Falling Today?
08:11am, Tuesday, 03'rd Mar 2026
Harrow stock drops after earnings miss and weak 2026 outlook, despite revenue growth and new product plans.
NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug
Harrow (HROW) Misses Q4 Earnings Estimates
07:00pm, Monday, 02'nd Mar 2026
Harrow (HROW) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.25 per share a year ago.
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
04:05pm, Monday, 02'nd Mar 2026
Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 mil
